Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos NV    GLPG   BE0003818359


Real-time Estimate Quote. Real-time Estimate Tradegate - 10/29 04:57:14 am
102.7 EUR   -0.39%
10/27GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program
10/27GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program
10/27Galapagos' R&D Roundtable showcases Toledo program
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Correction: Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis

share with twitter share with LinkedIn share with facebook
09/25/2020 | 03:14am EDT

Filgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials

Mechelen, Belgium; 25 September 2020, 08.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports that Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.  

Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA. The companies will jointly commercialize the medicine to make it available to physicians and patients across Japan.

For more information, please see Gilead’s full press release on www.gilead.com.

Gilead is developing Jyseleca in collaboration with Galapagos. The two companies are conducting global studies investigating the potential role of Jyseleca in a variety of diseases, including the previously reported Phase 3 SELECTION trial in ulcerative colitis.

About Galapagos
Galapagos discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Galapagos Contacts

Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15

Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent risks associated with clinical trial and product development activities, competitive developments, and regulatory approval requirements, including the risk that data from the ongoing and planned clinical research programs with filgotinib may not support registration or further development due to safety, efficacy or other reasons, the timing or likelihood of additional regulatory authorities approval of marketing authorization for filgotinib, such additional regulatory authorities requiring additional studies, Galapagos’ reliance on collaborations with third parties, including the collaboration with Gilead for filgotinib, the uncertainty regarding estimates of the commercial potential of filgotinib, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.


Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about GALAPAGOS NV
10/27GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program
10/27GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program
10/27Galapagos' R&D Roundtable showcases Toledo program
10/16GALAPAGOS : And servier report topline results for roccella phase 2 clinical tri..
10/16Oxurion NV Business Update, Q3 2020
10/15GALAPAGOS : Servier Knee Osteoarthritis Trial Fails to Meet Primary, Secondary E..
10/15GALAPAGOS : and Servier report topline results for ROCCELLA Phase 2 clinical tri..
10/15GALAPAGOS : and Servier report topline results for ROCCELLA Phase 2 clinical tri..
10/15Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical tr..
10/14Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
More news
Sales 2020 554 M 651 M 651 M
Net income 2020 -252 M -296 M -296 M
Net cash 2020 3 631 M 4 264 M 4 264 M
P/E ratio 2020 -29,7x
Yield 2020 -
Capitalization 6 737 M 7 920 M 7 911 M
EV / Sales 2020 5,60x
EV / Sales 2021 7,30x
Nbr of Employees 1 280
Free-Float 74,5%
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 134,44 €
Last Close Price 103,10 €
Spread / Highest target 55,2%
Spread / Average Target 30,4%
Spread / Lowest Target 11,5%
EPS Revisions
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Operating & Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS NV-44.72%7 920
LONZA GROUP AG63.59%47 362
SEAGEN INC.70.51%34 263
CELLTRION, INC.32.04%28 321
MODERNA, INC.240.08%27 885